A compound of formula (I) wherein R 1 is selected from i) H, ii) C 1-6 -alkyl, and iii) halogen; R 3 is halogen; R 4 is selected from i) H, ii) C 1-6 -alkyl, and iii) halogen; R 5 is selected from i) phenyl substituted with R 6 and optionally further substituted by R 7 and R 8 , ii) pyridinyl substituted with R 6 and optionally further substituted by R 7 and R 8 , and iii) pyrimidinyl substituted with R 6 and optionally further substituted by R 7 and R8; R 6 is selected from i) piperazinyl optionally substituted by R 9 , R 11 and R 12 , ii) piperidinyl optionally substituted by R 9 , R 11 and R 12 , and iii) morpholinyl optionally substituted by R 9 , R 11 and R 12 ; R 7 and R 8 are independently selected from i) C 1-6 -alkyl, ii) C 1-6 -alkoxy, iii) halo-C 1-6 -alkyl, iv) halo-C 1-6 -alkoxy, v) C 3-8 -cycloalkyl, vi) C 3-8 -cycloalkoxy, vii) halogen, and viii) hydroxy; R 9 , R 11 and R 12 are independently selected from i) H, ii) halogen, iii) C 1-6 -alkyl, iv) halo-C 1-6 -alkyl,and v) C 3-8 -cycloalkyl; R 10 is selected from i) H, and ii) C 1-6 -alkyl, iii) C 3-8 -cycloalkyl, and iv) halogen; wherein halogen is at each instance independently selected from fluoro and chloro; or pharmaceutically acceptable salts. R 1 is selected from i) H, ii) C 1-6 -alkyl, and iii) halogen; i) H, ii) C 1-6 -alkyl, and iii) halogen; R 3 is halogen; R 4 is selected from i) H, ii) C 1-6 -alkyl, and iii) halogen; i) H, ii) C 1-6 -alkyl, and iii) halogen; R 5 is selected from i) phenyl substituted with R 6 and optionally further substituted by R 7 and R 8 , ii) pyridinyl substituted with R 6 and optionally further substituted by R 7 and R 8 , and iii) pyrimidinyl substituted with R 6 and optionally further substituted by R 7 and R8; i) phenyl substituted with R 6 and optionally further substituted by R 7 and R 8 , ii) pyridinyl substituted with R 6 and optionally further substituted by R 7 and R 8 , and iii) pyrimidinyl substituted with R 6 and optionally further substituted by R 7 and R8; R 6 is selected from i) piperazinyl optionally substituted by R 9 , R 11 and R 12 , ii) piperidinyl optionally substituted by R 9 , R 11 and R 12 , and iii) morpholinyl optionally substituted by R 9 , R 11 and R 12 ; i) piperazinyl optionally substituted by R 9 , R 11 and R 12 , ii) piperidinyl optionally substituted by R 9 , R 11 and R 12 , and iii) morpholinyl optionally substituted by R 9 , R 11 and R 12 ; R 7 and R 8 are independently selected from i) C 1-6 -alkyl, ii) C 1-6 -alkoxy, iii) halo-C 1-6 -alkyl, iv) halo-C 1-6 -alkoxy, v) C 3-8 -cycloalkyl, vi) C 3-8 -cycloalkoxy, vii) halogen, and viii) hydroxy; i) C 1-6 -alkyl, ii) C 1-6 -alkoxy, iii) halo-C 1-6 -alkyl, iv) halo-C 1-6 -alkoxy, v) C 3-8 -cycloalkyl, vi) C 3-8 -cycloalkoxy, vii) halogen, and viii) hydroxy; R 9 , R 11 and R 12 are independently selected from i) H, ii) halogen, iii) C 1-6 -alkyl, iv) halo-C 1-6 -alkyl,and v) C 3-8 -cycloalkyl; i) H, ii) halogen, iii) C 1-6 -alkyl, iv) halo-C 1-6 -alkyl,and v) C 3-8 -cycloalkyl; R 10 is selected from i) H, and ii) C 1-6 -alkyl, iii) C 3-8 -cycloalkyl, and iv) halogen; i) H, and ii) C 1-6 -alkyl, iii) C 3-8 -cycloalkyl, and iv) halogen; wherein halogen is at each instance independently selected from fluoro and chloro; or pharmaceutically acceptable salts. <EOS>